Clinical Trial

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical…

2 years ago

Bio-Path Holdings Provides Clinical Update and Expansion Plans

Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for…

2 years ago

Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply

Collaboration aims to develop innovative production methods to increase global availability of vegetables, shorten supply chains and promote sustainable agricultureHAIFA,…

2 years ago

Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences

TuHURA has an exclusive right to negotiate to acquire Kineta’s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million…

2 years ago

Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

2 years ago

Signum Surgical Granted FDA De Novo Clearance for BioHealx™

Novel surgical option for the treatment of anal fistula, a painful and debilitating colorectal condition Milestone follows recent completion of…

2 years ago

Breast Tissue Expander Market size is set to grow by USD 282.4 million from 2024-2028, Increasing prevalence of breast cancer boost the market, Technavio

NEW YORK, July 4, 2024 /PRNewswire/ -- The global breast tissue expander market size is estimated to grow by USD 282.4 million…

2 years ago

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia…

2 years ago

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives…

2 years ago

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more…

2 years ago